Aimfinity Investment Corp. I’s Schedule 13G amendment reports that Polar Asset Management Partners Inc., investment advisor to Polar Multi-Strategy Master Fund with respect to shares directly held by the fund, has beneficial ownership of 0 AIMTF Class A ordinary shares (0%). It reports zero sole and shared voting power and zero sole and shared dispositive power, and identifies the reporting person under the ownership-of-5%-or-less category. The statement was signed by Andrew Ma, Chief Compliance Officer.
Aimfinity Investment Corp. I filed a Form 8-K reporting additions to the board of the combined public company and business development updates for Docter, the target business in the pending merger.
The filing names William Frank Koschak and Jonathan Bond as independent director nominees for PubCo, notes Mr. Koschak is designated as an audit committee financial expert, and states each independent director will receive 20,000 PubCo Ordinary Shares annually. The filing also discloses early commercial activity for Docter: a first product shipment to a Taiwan SECOM subsidiary valued at NT$1.66 million and an initial 300-unit order from Leeway Biomedical valued at NT$2,268,000 (pre-tax), with preliminary customer discussions projecting larger potential demand (an estimated NT$75 million broader project and approximately 10,000 units with projected sales of USD 2.5 million).
Aimfinity Investment Corp. I reports additional governance and business developments tied to its pending business combination with Docter Inc. The future public company (PubCo) plans to add two independent directors, William Frank Koschak and Jonathan Bond, who will also sit on the audit, compensation, and nominating and governance committees. The board has determined that both are independent under Nasdaq rules and that Koschak qualifies as an audit committee financial expert.
The filing also highlights early commercial traction for Docter. Docter completed a first shipment to a Taiwan SECOM subsidiary valued at about NT$1.66 million, which management describes as part of a broader project estimated at approximately NT$75 million. A separate customized order from Leeway Biomedical covers 300 iCARE sleep sensing devices worth roughly NT$2,268,000, with discussions indicating potential expansion to about 10,000 units and projected total sales of around USD 2.5 million if testing is successful. Docter additionally outlines several hospital projects expected to move forward over the next three months using its mmWave technology, all subject to competitive public tenders with no assurance of award. Independent directors of PubCo are expected to receive annual compensation of 20,000 PubCo Ordinary Shares.
Aimfinity Investment Corp. I extended its SPAC combination deadline and issued a promissory note. The company accepted two one-month extensions by depositing $500 each into its trust account, moving the deadline first to April 28, 2026 and then to May 28, 2026. The Extensions are the sixth and seventh permitted under the Charter, which allows up to nine Monthly Extensions to July 28, 2026. The company issued an unsecured promissory note dated May 5, 2026 for up to $2,000; $1,000 has been drawn as of May 6, 2026. Outstanding amounts convert at $10.00 per PubCo ordinary share upon closing of the Business Combination with Docter Inc.
Aimfinity Investment Corp. I disclosed that its sponsor’s designee, I‑Fa Chang, deposited $500 into the SPAC’s trust account on both March 28, 2026 and April 28, 2026, triggering one‑month extensions of the deadline to complete its initial business combination, first to April 28, 2026 and then to May 28, 2026.
These were the sixth and seventh of up to nine permitted monthly extensions under the current charter, each requiring a $500 deposit. In connection with these and prior loans, the company issued an unsecured promissory note dated May 5, 2026 to Mr. Chang with a principal amount of up to $2,000, of which $1,000 had been drawn as of May 6, 2026.
The note bears no regular interest, with default interest tied to the prevailing short‑term U.S. Treasury Bill rate, and is repayable upon completion of Aimfinity’s initial business combination or liquidation. Under an exchange agreement related to Aimfinity’s planned business combination with Docter Inc., any outstanding balance on the note at closing will automatically convert into PubCo ordinary shares at a conversion price of $10.00 per share. The note was issued under a private offering exemption from registration.
Aimfinity Investment Corp. I filed a Form 12b-25 notification stating it could not timely file its Annual Report on Form 10-K for the period ended December 31, 2025. The company says it needs additional time to assemble information and anticipates filing the Form 10-K no later than the fifteenth calendar day following the prescribed due date.
Aimfinity Investment Corp. I issued a $500 unsecured promissory note to a Sponsor designee to fund a one-month extension to consummate its initial business combination. The payment extends the combination deadline one month, from February 28, 2026 to March 28, 2026, and is the fifth of up to nine permitted monthly extensions. The Note, issued under an exemption from registration under Section 4(a)(2) of the Securities Act, will, unless repaid in part or in full, automatically convert at a conversion price of $10.00 per PubCo ordinary share upon closing of the Business Combination with Docter Inc.
Aimfinity Investment Corp. I entered into a small financing arrangement to extend the deadline for completing its initial business combination. On February 28, 2026, the company issued an unsecured promissory note for $500 to I-Fa Chang, designated by the sponsor, and deposited the same amount into its trust account as a monthly extension payment.
This fifth of up to nine allowed extensions moves the business combination deadline from February 28, 2026 to March 28, 2026. Under an existing exchange agreement, the note balance will automatically convert into PubCo ordinary shares at $10.00 per share upon closing the proposed business combination with Docter Inc., unless repaid earlier. The note was issued under a private placement exemption, and the company also released a press statement announcing the extension.
Aimfinity Investment Corp. I received an amended Schedule 13G/A showing that a group of Harraden Circle investment entities and Frederick V. Fortmiller, Jr. now report beneficial ownership of 0 shares, or 0%, of the Class A common stock as of 12/31/2025.
The filing states this is an exit filing, confirming that these reporting persons have ceased to be beneficial owners of more than five percent of Aimfinity’s Class A shares and no longer hold voting or dispositive power over the stock.